From August 7, 2025
MINNEAPOLIS–(BUSINESS WIRE)–HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including K5 Global, Bezos Expeditions, Wellington Management and other new and existing investors. The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of the Edison System across new clinical indications and global markets.
What is HistoSonics?
HistoSonics is a medical device company that pioneered histotripsy—a non-invasive, focused ultrasound technology that mechanically destroys unwanted tissue at a sub-cellular level. Founded in 2009 based on research from the University of Michigan, the company is headquartered in Ann Arbor and Plymouth, Michigan. They’ve raised $300M in venture funding, including a $102M Series D round in 2024.
It’s Called the Edison Histotripsy System
- Edison System: A sophisticated, robotically assisted platform delivering pulsed sound energy to liquefy targeted tumors without surgery or heat.
- Mechanism: Ultrasound-induced acoustic cavitation forms microbubble clouds that collapse in microseconds, mechanically destroying tissue—preserving critical structures like blood vessels and bile ducts.
Milestones
- FDA Approval:
- Received Breakthrough Device Designation (2021).
- Granted De Novo clearance in October 2023 for treating liver tumors.
- HOPE4LIVER Trials:
- Treated 47 patients across multiple centers; 95.5% achieved complete tumor coverage.
- 12-month follow-up reported a 90% local tumor control rate with minimal complications.
- HOPE4KIDNEY Trial:
- Clinical treatments underway for kidney tumors; first procedure performed in Florida (2024).
- Other Indications:
- Active efforts are underway to expand histotripsy into treating pancreatic tumors and potentially other solid tumors or benign conditions like fibroids and enlarged prostates.
Summary Table
| Aspect | Details |
|---|---|
| Technology | Non-invasive histotripsy via focused ultrasound (Edison System) |
| Clinical Status | FDA-approved for liver tumors; trials underway for kidney, pancreas |
| Performance | ~90% local tumor control at 12 months (HOPE4LIVER) |
| Funding & Valuation | $300M+ raised; ~$2.25B valuation post-acquisition |
| Next Steps | Expanding to new indications, scaling global access, potential partnerships/acquisition |
HistoSonics is at the very forefront of transforming tumor treatment with non-invasive, ultrasound-based histotripsy. Their Edison system offers precise, thermal-free tumor destruction—showing exceptional trial results and expanding rapidly across multiple therapeutic areas. Financially, the company has gained strong investor interest and is entering a pivotal growth phase.
